First line treatment for metastatic renal cell carcinoma in Colombia : a cost-effectiveness analysis.

id	metarevistapublica_acho_revistacolombianadehematologiayoncologia_27-article-310
record_format	ojs
spelling	First line treatment for metastatic renal cell carcinoma in Colombia : a cost-effectiveness analysis. Becerra, Henry Revista colombiana de hematología y oncología Bogotá: Asociación Colombiana de Hematología y Oncología, 2012- Artículo de revista Núm. 3 , Año 2012 : Septiembre 3 1 Gis, Paul Cardona, Andrés Felipe Carranza, Hernán Pacheco, Javier Godoy, Javier Cáceres, Heidy Otero, Jorge Miguel Luján, Mauricio Spath, Alfredo Lopera, Diego Journal article Bukowski RM, Eisen T, Szczylik C, Stadler WM, Simantov R, Shan M, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol. 2007;(May 20 suppl). Abstract 5023. Trippoli S, Messori A. Cost effectiveness of sunitinib. J Clin Oncol. 2008;26(35):5829. Gill S, Sargent D. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival? Oncologist 2006;11(6):624-9. Chabot I, LeLorier J, Blackstein ME. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumour. Eur J Cancer. 2008;44(7):972-7. Allareddy V, Konety BR. Inpatient costs for bladder, kidney, and prostate cancers in the year 2002. A study using the NIS sample. American Urological Association Annual Meeting, May 20-25, 2006. Abstract 232. Lefebvre C, Lusher A, Dickersin K, Manheimer E. Literature searches. Lancet. 2002;359(9309):896. Heng DY, Chi KN, Murray N, Jin T, Garcia JA, Bukowski RM, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer. 2009;115(4):776-83. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-90. Commission on Macroeconomics and Health, World Health Organization (WHO). Macroeconomics and health: investing in health for economic development. Geneva: World Health Organization; 2001. Remák E, Charbonneau C, Négrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol. 2008;26(24):3995-4000. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584-90. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med. 1998;338(18):1272-8. Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, et al. Randomized phase II trial of first-line treatment with Sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. J Clin Oncol. 2007;25(18S):5025. Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28(13):2144-50. Godoy JI, Cardona AF, Alvis N, Arango CH, Romero C, Spath A, et al. Sunitinib vs. interferon-alfa (IFN) for first-line treatment of metastatic renal cell carcinoma (mRCC) in Colombia: an economic evaluation. Rev Colomb Cancerol. 2008;12(2):63-73. Weibull W. A statistical distribution function of wide applicability. J Appl Mech Trans ASME. 1951;18(3):293-7. Negrier S, Figlin RA, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (MRCC). European Society Medical Oncology (ESMO) 2008. Abstract 588. Mickisch G, Escudier BJ, Gore ME, Walzer S, Sabaté E, Nuijten M. Costs of managing side effects in the treatment of first-line metastatic renal cell carcinoma (mRCC) in Germany, France, and UK: Bevacizumab (BEV) + interferon alpha-2a (IFN) compared with sunitinib. J Clin Oncol. 2008;26(May 20 suppl). Abstract 5110. Coppin C, Le L, Porzsolt F, Wilt T. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev. 2008;(2):CD006017. http://purl.org/coar/resource_type/c_6501 Text http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess http://purl.org/coar/version/c_970fb48d4fbd8a85 info:eu-repo/semantics/publishedVersion http://purl.org/redcol/resource_type/ART http://purl.org/coar/resource_type/c_2df8fbb1 info:eu-repo/semantics/article Benedict A, Charbonneau C, Kim ST, Négrier S. Cost-effectiveness of sunitinib, sorafenib, temsirolimus, and bevacizumab + interferon-alfa as first-line therapy for metastatic renal cell carcinoma: an indirect comparison. European Society Medical Oncology (ESMO) 2008. Abstract 723. https://revista.acho.info/index.php/acho/article/download/310/277 Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2007;25(18S):5023. Murillo R, Quintero A, Piñeros M, Bravo MM, Cendales R, Wiesner C, et al. Modelo para el control del cáncer en Colombia. URL available from: (accessed in June 2012). Procopio G, Verzoni E, Bajetta E, Giuliani G, Peccerillo C, Walzer S, et al. Cost of managing side effects in the treatment of first-line metastatic renal cell carcinoma in Italy: bevacizumab + interferon alpha-2ª compared with sunitinib. Ann Oncol. 2008;(Oct 20 suppl.). Abstract 601. Munir U, Benedict A, Borgman B, Sandin R, Harmenberg U, Ullén A, et al. Cost-effectiveness of sunitinib vs. sorafenib, temsirolimus and bevacizumab + interferon-alfa as first-line therapy for metastatic renal cell carcinoma - Adaptation for the Swedish Health Service. European Society Medical Oncology (ESMO) 2008. Abstract 725. Díaz S, Calvo Aller E, Maroto P, Puente J, López-Brea M, Castellano D. Cost-effectiveness and cost-utility analysis of sunitinib vs. sorafenib and bevacizumab + interferon-alfa as firstline treatment for metastatic renal cell carcinoma in Spain. European Society Medical Oncology (ESMO) 2008. Abstract 724. Benedict A, Charbonneau C, Hidi J, Kim ST, Négrier S. Economic evaluation of sunitinib, sorafenib, bevacizumab/interferon-alfa and temsirolimus for first line treatment of metastatic renal cell carcinoma (mRCC): a cost-effectiveness analysis. J Clin Oncol. 2008;(May 20 suppl). Abstract 5048. Martínez F, Robayo G, Valencia O. Desarrollo del principio de universalidad en el Sistema General de Seguridad Social en Salud: a ocho años de la reforma en Colombia. Acemi, Fedesalud; 2002. URL available from: (accessed in June 2012). Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007;29(7):1338-53. Globocan 2000. Lyon: International Agency for Research on Cancer; 2000. URL available from: (accessed in June 2012). metastatic 2256-2915 2256-2877 application/pdf 2012-09-01 2012-09-01 00:00:00 2012-09-01 00:00:00 targeted therapy Colombia 10.51643/22562915.310 cost effectiveness analysis renal cell carcinoma terapia dirigida metástasis Colombia análisis de costo-efectividad carcinoma de células renales https://revista.acho.info/index.php/acho/article/view/310 https://doi.org/10.51643/22562915.310 Orozco JM. Los costos del plan obligatorio de salud subsidiado en Colombia. 2006. URL available from: (accessed in June 2012). Motzer RJ, Figlin RA, Hutson TE, Tomczak P, Bukowski RM, Rixe O, et al. Sunitinib versus interferon-alfa (IFN) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. J Clin Oncol. 2007 ASCO Annual Meeting Proceedings Part I. 2007;25(18S):5024. Pouessel D, Culine S. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel. Expert Rev Anticancer Ther. 2006;6(12):1761-7. Halbert RJ, Figlin RA, Atkins MB, Bernal M, Hutson TE, Uzzo RG, et al. Treatment of patients with metastatic renal cell cancer: a RAND Appropriateness Panel. Cancer. 2006;107(10):2375-83. Rini BI, Campbell SC, Rathmell WK. Renal cell carcinoma. Curr Opin Oncol. 2006;18(3):289-96. Mirra AP, Latorre MRDO, Veneziano DB (eds.). Cancer incidence in the city of São Paulo, Brazil, 1997-1998. Cancer mortality in the city of São Paulo, Brazil. Trends in the period 1969-1998. Brasília, DF: Ministério da Saúde; 2001. Salvadó JA, Domínguez J, Velasco A, Bustamente A, Troncoso P, Pinochet R, et al. Factores pronósticos en carcinoma de células renales: ¿son adecuadas las variables definidas por el actual TNM? Rev Chil Urol. 2006;71(2):141-46. Wünsch-Filho V. Insights on diagnosis, prognosis and screening of renal cell carcinoma. Sao Paulo Med J. 2002;120(6):165-4. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, Horner MJ, et al., editors. SEER Cancer Statistics Review, 1975- 2005. Bethesda, MD: National Cancer Institute, http://seer.cancer.gov/csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin. 2007;57(1):43-66. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006;98(18):1331-4. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281(17):1628-31. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-24. 23 15 Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. https://creativecommons.org/licenses/by-nc-sa/4.0 Publication
institution	ASOCIACION COLOMBIANA DE HEMATOLOGIA Y ONCOLOGIA
thumbnail	https://nuevo.metarevistas.org/ASOCIACIONCOLOMBIANADEHEMATOLOGIAYONCOLOGIA/logo.png
country_str	Colombia
collection	Revista Colombiana de Hematología y Oncología
title	First line treatment for metastatic renal cell carcinoma in Colombia : a cost-effectiveness analysis.
spellingShingle	First line treatment for metastatic renal cell carcinoma in Colombia : a cost-effectiveness analysis. Becerra, Henry Gis, Paul Cardona, Andrés Felipe Carranza, Hernán Pacheco, Javier Godoy, Javier Cáceres, Heidy Otero, Jorge Miguel Luján, Mauricio Spath, Alfredo Lopera, Diego metastatic targeted therapy Colombia cost effectiveness analysis renal cell carcinoma terapia dirigida metástasis Colombia análisis de costo-efectividad carcinoma de células renales
title_short	First line treatment for metastatic renal cell carcinoma in Colombia : a cost-effectiveness analysis.
title_full	First line treatment for metastatic renal cell carcinoma in Colombia : a cost-effectiveness analysis.
title_fullStr	First line treatment for metastatic renal cell carcinoma in Colombia : a cost-effectiveness analysis.
title_full_unstemmed	First line treatment for metastatic renal cell carcinoma in Colombia : a cost-effectiveness analysis.
title_sort	first line treatment for metastatic renal cell carcinoma in colombia : a cost-effectiveness analysis.
author	Becerra, Henry Gis, Paul Cardona, Andrés Felipe Carranza, Hernán Pacheco, Javier Godoy, Javier Cáceres, Heidy Otero, Jorge Miguel Luján, Mauricio Spath, Alfredo Lopera, Diego
author_facet	Becerra, Henry Gis, Paul Cardona, Andrés Felipe Carranza, Hernán Pacheco, Javier Godoy, Javier Cáceres, Heidy Otero, Jorge Miguel Luján, Mauricio Spath, Alfredo Lopera, Diego
topic	metastatic targeted therapy Colombia cost effectiveness analysis renal cell carcinoma terapia dirigida metástasis Colombia análisis de costo-efectividad carcinoma de células renales
topic_facet	metastatic targeted therapy Colombia cost effectiveness analysis renal cell carcinoma terapia dirigida metástasis Colombia análisis de costo-efectividad carcinoma de células renales
citationvolume	1
citationissue	3
citationedition	Núm. 3 , Año 2012 : Septiembre
publisher	Bogotá: Asociación Colombiana de Hematología y Oncología, 2012-
ispartofjournal	Revista colombiana de hematología y oncología
source	https://revista.acho.info/index.php/acho/article/view/310
language
format	Article
rights	http://purl.org/coar/access_right/c_abf2 info:eu-repo/semantics/openAccess Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0. https://creativecommons.org/licenses/by-nc-sa/4.0
type_driver	info:eu-repo/semantics/article
type_coar	http://purl.org/coar/resource_type/c_6501
type_version	info:eu-repo/semantics/publishedVersion
type_coarversion	http://purl.org/coar/version/c_970fb48d4fbd8a85
type_content	Text
publishDate	2012-09-01
date_accessioned	2012-09-01 00:00:00
date_available	2012-09-01 00:00:00
url	https://revista.acho.info/index.php/acho/article/view/310
url_doi	https://doi.org/10.51643/22562915.310
issn	2256-2877
eissn	2256-2915
doi	10.51643/22562915.310
citationstartpage	15
citationendpage	23
url2_str_mv	https://revista.acho.info/index.php/acho/article/download/310/277
_version_	1823468244802994176

First line treatment for metastatic renal cell carcinoma in Colombia : a cost-effectiveness analysis. .

Código QR

Estadísticas y Métricas Alternativas

Títulos similares

First line treatment for metastatic renal cell carcinoma in Colombia : a cost-effectiveness analysis.
.